New pill takes on tough cancers: first human trial launches
NCT ID NCT06801002
First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 29 times
Summary
This early-stage study tests a new oral drug, JBZ-001, in about 25 adults with advanced solid tumors or certain blood cancers that have not responded to standard treatments. The main goals are to find a safe dose and to see if the drug can shrink tumors or control the disease. Participants will receive increasing doses of JBZ-001 and be closely monitored for side effects and signs of benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact
Contact Email: •••••@•••••
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Conditions
Explore the condition pages connected to this study.